Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2204]

$FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma$

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

FDA grants accelerated approval to lurbinectedin for metastatic small cell lung cancer

FDA approves gemtuzumab ozogamicin for CD33-positive AML in paediatric patients

FDA approves gemtuzumab ozogamicin for CD33-positive AML in paediatric patients

FDA approves pembrolizumab for adults and children with TMB-H solid tumours

FDA approves pembrolizumab for adults and children with TMB-H solid tumours

Cancer patients less likely to be prescribed cardioprotective medications

Cancer patients less likely to be prescribed cardioprotective medications

Phase II trial leads to practice changing milestone for advanced anal cancer

Phase II trial leads to practice changing milestone for advanced anal cancer

FDA approves nivolumab for oesophageal squamous cell carcinoma

FDA approves nivolumab for oesophageal squamous cell carcinoma

$European Commission approves isatuximab for adults with relapsed and refractory multiple myeloma$

European Commission approves isatuximab for adults with relapsed and refractory multiple myeloma

European Commission approves encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer

European Commission approves encorafenib in combination with cetuximab for the treatment of adult patients with...

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

More from ecancer